100–200 mg/day with a fatty meal; ubiquinol is better absorbed.
As an add-on, it improves symptoms and reduces events.
View the study (clinical trial) →May help some people; the evidence is inconsistent.
View the study (meta-analysis) →⏱ 3 min read
Coenzyme Q10, also called ubiquinone in its oxidized form and ubiquinol in its reduced form, is a molecule that the body synthesizes endogenously and that serves two critical functions: it is an essential component of the mitochondrial respiratory chain (it carries electrons between complexes I/II and III, an indispensable step for ATP synthesis) and it is one of the main fat-soluble antioxidants, protecting cell membranes and LDL lipoproteins from oxidative damage.
Endogenous CoQ10 synthesis peaks around age 25 and falls progressively with age, especially in organs with high energy demand such as the heart, skeletal muscle, and brain; this decline is accentuated by the use of statins (which inhibit the same mevalonate pathway needed to synthesize CoQ10), which has generated one of the most interesting clinical debates about CoQ10 supplementation in cardiovascular patients.
The most robust evidence for CoQ10 comes from the Q-SYMBIO trial published in 2014: 420 patients with advanced heart failure (NYHA III–IV) treated with 300 milligrams daily of CoQ10 for 2 years showed a 43 percent reduction in the combined primary endpoint (cardiovascular death or hospitalization for heart failure) and a 42 percent reduction in all-cause mortality compared with placebo, an effect quantitatively comparable to that of first-line cardioprotective drugs.
These results, partly replicated by smaller studies, have led several cardiology guidelines (especially European ones) to mention CoQ10 as a reasonable adjunct in heart failure, although its incorporation into standard treatment remains uneven across countries and among cardiologists; the effective doses are high (200–300 mg/day) and the clinical response usually takes 2–3 months to become evident.
Statins block HMG-CoA reductase, an enzyme shared by the cholesterol and CoQ10 synthesis pathways, which reduces plasma and muscle CoQ10 levels by 30 to 40 percent in people treated chronically; the reasonable hypothesis is that this deficiency contributes to statin-induced myalgias, one of the most frequent patient complaints and a common reason for discontinuing lipid-lowering treatment.
Meta-analyses of CoQ10 supplementation for statin myalgia show mixed results but point to a modest benefit in people with significant symptoms: doses of 100–200 milligrams daily for 4–12 weeks reduce subjective muscle pain in some studies, although others find no significant effect; the heterogeneity probably reflects differences in formulation, dose, and subtype of myalgia (real vs. nocebo effect).
In migraine prophylaxis, several randomized trials have shown 30–50 percent reductions in monthly frequency with doses of 100–300 milligrams daily for 2–3 months, an effect that places it, along with riboflavin and magnesium, among the few nutritional interventions with evidence for preventing migraines in patients with several attacks per month.
In male fertility, several trials have shown improvements in sperm motility and morphology with 200–300 milligrams daily for 3–6 months, especially in men with idiopathic asthenospermia; in mild hypertension, meta-analyses show modest reductions in systolic pressure on the order of 5–10 mmHg that add to other interventions; in primary mitochondrial diseases, CoQ10 can be an essential tool under genetic supervision.
CoQ10 is sold in two commercial forms: ubiquinone (the oxidized form, more stable and cheaper) and ubiquinol (the reduced form, biologically active but more expensive); ubiquinol has better oral bioavailability, especially in people over 60 whose ability to reduce ubiquinone declines with age, which justifies paying the extra cost in that demographic group; in young, healthy people, conventional ubiquinone taken with a fatty meal has sufficient bioavailability to achieve clinical effects.
The doses studied range from 100 to 300 milligrams daily, divided into one or two doses with a meal containing fat (because absorption is highly dependent on the lipid matrix); clinical effects on cardiovascular markers appear within 4 to 12 weeks, in migraine they can take 2 months, and in heart failure they may require 3 months for full functional improvement.
It has an excellent safety profile: adverse effects are rare and mild (digestive discomfort at high doses, rarely insomnia if taken very late); people who take warfarin should be cautious because CoQ10 can slightly reduce the anticoagulant effect owing to its chemical structure shared with vitamin K, an interaction that should be monitored with INR when starting supplementation.
Information, not medical advice. Scientific evidence reflects the quality of the studies.